What is Theravance Biopharma's AFS securities?

Theravance Biopharma (TBPH) reported AFS securities of $11.13M in Q4 2025.

What does AFS securities mean?

Debt securities classified as available-for-sale, measured at fair value with unrealized gains/losses in OCI rather than the income statement.

Theravance Biopharma TBPH AFS Securities

AFS Securities at other companies

Zevra Therapeutics, Inc.ZVRA

$36.1M+493%

Royalty PharmaRPRX

$406.8M+85.8%

PrecigenPGEN

$489K-34.8%

Ultragenyx PharmaceuticalRARE

$121M+76.5%

Mirum Pharmaceuticals, Inc.MIRM

$34.35M+64.3%

Other financials

Income statement

See full

Revenue$17.7M+15.0%

Operating income-$9.5M+34.3%

Net income-$4.9M+63.7%

EPS (diluted)-$0.10+63.0%

Balance sheet

See full

Cash & equivalents$288.1M+160%

Total debt$40.5M-15.9%

Total equity$290.6M+75.1%

Total assets$472.3M+37.5%

Cash flow

See full

Operating cash flow$73.3M+70.3%

CapEx$8.0K-95.8%

Free cash flow$59.6M+5,560%

Valuation

See full

Market cap$896.51M+68.7%

Enterprise value$648.91M+38.3%

P/E7.8×—

P/S8.2×0.0×

Profitability

See full

Gross margin60.8%—

Operating margin1.2%+0.6pp

Net margin104.3%+71.4pp

FCF margin221.9%+206pp

Returns & leverage

See full

Return on equity50.2%+36.2pp

Debt / equity0.1×-0.2×

Current ratio13.1×+8.4×

Where this comes from

Reported directly by Theravance Biopharma in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent.

The official record: Theravance Biopharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Theravance Biopharma's afs securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Theravance Biopharma's AFS securities?: Theravance Biopharma (TBPH) reported AFS securities of $11.13M in Q4 2025.
What does AFS securities mean?: Debt securities classified as available-for-sale, measured at fair value with unrealized gains/losses in OCI rather than the income statement.